PITTSBURGH , May 19, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, is pleased to present new data entitled “GEM-3: phase 3 safety and immunogenicity results of beremagene geperpavec (B-VEC), an investigational, topical gene

Biologics License Application for B-VEC remains on track to file in the US in 2Q 2022 and Marketing Authorization in the EU on track to file in 2H 2022 FDA allows dosing at a patient’s home in the Open Label Extension Study of B-VEC for the treatment of DEB Positive Clinical Phase 1 (Pearl-1 Study)

PITTSBURGH , May 03, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. , (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in the Bank of America Merrill Lynch Global Healthcare

April 28, 2022 Download PDF PITTSBURGH, April 28, 2022 (GLOBE NEWSWIRE) --  Jeune Aesthetics, Inc. (“Jeune Aesthetics”), a wholly-owned subsidiary of  Krystal Biotech, Inc.  (“Krystal”) (NASDAQ: KRYS) today announced the formation and members of its Scientific Advisory Board, comprised of industry

PITTSBURGH , April 11, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies, today announced that it plans to offer patients with dystrophic epidermolysis bullosa (DEB), who are enrolled in the GEM-3 open label extension study, the

Treatment with B-VEC demonstrated robust functional COL7 expression followed by its assembly into basement membrane-associated anchoring fibrils Treatment with B-VEC improved durable wound closure in patients with recessive dystrophic epidermolysis bullosa (RDEB) compared with placebo with minimal

PITTSBURGH , March 26, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . , (“ Krystal Biotech”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, presented more detailed results from the GEM-3 Phase 3 study of beremagene geperpavec (B-VEC), an investigational, topical gene

PITTSBURGH , March 24, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan , Chairman and Chief Executive Officer, will participate in H.C. Wainwright’s Gene Therapy and Gene Editing Conference and

Positive proof-of-concept efficacy data supports advancing into Phase 2 studies Adverse events, associated with injection site reactions, were mild and transitory Conference call to discuss results scheduled for Tuesday, March 22, 2022 at 8:00 a.m. ET PITTSBURGH, March 22, 2022 (GLOBE NEWSWIRE) --

PITTSBURGH , March 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present late-breaking research at the 2022 American Academy of Dermatology Annual Meeting, taking place March

PITTSBURGH , March 15, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced it has reached a binding term sheet with PeriphaGen, Inc. (“PeriphaGen”) to resolve all claims in the trade secret litigation

Following successful completion of GEM-3 pivotal trial, Krystal is on track to file BLA for Vyjuvek™ for the treatment of dystrophic epidermolysis bullosa in 1H 2022; MAA filing anticipated in 2H 2022 Phase 1 trial of KB407 in cystic fibrosis patients in Australia expected to begin in 1H 2022; IND

PITTSBURGH , Feb. 24, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat at Cowen’s 42nd Annual Health Care Conference,

PITTSBURGH , Jan. 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare disease, announced today the appointments of Jing Marantz as Chief Business Officer and Rand Sutherland as a new member of the Board of Directors. Dr.

PITTSBURGH, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc., a wholly-owned subsidiary of  Krystal Biotech, Inc. , (“Krystal”) (NASDAQ: KRYS), today announced that Bhushan Hardas, MD, MBA, President, Jeune Aesthetics, will participate on the panel titled “State of Aesthetic Industry

PITTSBURGH , Nov. 30, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has priced the previously announced underwritten public offering of 2,666,667 shares of its common stock, at a

PITTSBURGH , Nov. 29, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has commenced a $200 million underwritten public offering of its common stock.

•  Pivotal GEM-3 trial met its primary endpoint of complete wound healing at six-month timepoints, and its secondary endpoint of complete wound healing at three-month timepoints VYJUVEK TM was well tolerated, with no drug-related serious adverse events or discontinuations Biologics License

Pre-clincal program evaluated proper formation and deposition of elastic fibers into the skin extracellular matrix in mice KB303 holds potential to be the first-ever directed approach to increase production of elastin in the skin PITTSBURGH, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc.,

–  Top-line results from the pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (DEB) on track for 4Q21 –  Enrollment in Phase 1 proof-of-concept study (PEARL-1 study) to treat aesthetic skin conditions is complete –  Strong balance sheet with September 30, 2021 cash, cash

Topline results anticipated in the fourth quarter of 2021 Of the 31 patients enrolled in the trial, 29 patients completed the study with no missing visits, including the three primary endpoint assessment visits PITTSBURGH , Oct. 26, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc.

PITTSBURGH , Oct. 19, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced the presentation of pre-clinical data describing the nonclinical pharmacology of nebulized KB407, a redosable gene therapy

PITTSBURGH , Oct. 14, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present pre-clinical pharmacology data on its second genetic pulmonary disease candidate KB408, for the treatment

PITTSBURGH , Oct. 01, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced its participation in the Chardan Virtual 5th Annual Genetic Medicines Conference , taking place October 4-5, 2021 .

-  KB407 is an investigational inhaled gene therapy derived from Krystal’s clinically validated redosable gene delivery technology platform PITTSBURGH , Sept. 29, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases,

PITTSBURGH , Sept. 15, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced the appointment of Laurent Goux as the General Manager of Europe . Mr. Goux has more than 20 years of global biotechnology

Data include evaluation of investigational B-VEC in a murine corneal wound model U.S. FDA has recently approved a compassionate use request for topical B-VEC application to one eye in a RDEB patient PITTSBURGH , Sept. 09, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc.

PITTSBURGH , Sept. 07, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced it will be featured as a presenting company at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference . The

Top-line data from the pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (“DEB”) on track for 4Q21 Initiation of Phase 1 study of inhaled KB407 for the treatment of cystic fibrosis expected in 3Q21 Our wholly-owned subsidiary Jeune Aesthetics, Inc.

KB301 is designed to deliver a full-length human type III collagen transgene via intradermal injection Initial data from this efficacy cohort of the PEARL-1 study is anticipated in 4Q21 PITTSBURGH, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc., a wholly-owned subsidiary of Krystal

-  New data include update from the fourth patient treated in the Phase 1/2 trial -  Repeat topical KB105 dosing continues to be well tolerated with no adverse events or evidence of immune response PITTSBURGH , July 01, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc.

PITTSBURGH , June 03, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced participation in two upcoming virtual investor conferences. Details for the events are as follows: Goldman Sachs 42nd Annual

Completed enrollment in pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (DEB) Strong balance sheet with March 31, 2021 cash, cash equivalents and short-term investments of $403.4 million PITTSBURGH , May 10, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc.

PITTSBURGH , May 03, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, announced today the appointment of Andy Orth as Chief Commercial Officer. Mr. Orth has more than 25 years of global biotechnology experience,

PITTSBURGH , April 27, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present preclinical data from its vector-encoded-antibody platform in a digital poster presentation at the

PITTSBURGH , April 26, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced modifications to the Statistical Analysis Plan (SAP) in the ongoing Phase 3 study of B-VEC for the treatment of dystrophic

New preclinical data from GLP toxicology and biodistribution study demonstrates in vivo safety of KB407 for cystic fibrosis Company expands rare genetic lung disease pipeline with KB408 for the treatment of alpha-1 antitrypsin deficiency PITTSBURGH , April 19, 2021 (GLOBE NEWSWIRE) -- Krystal

PITTSBURGH , March 30, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that enrollment is complete in the pivotal GEM-3 study of B-VEC for dystrophic epidermolysis bullosa (DEB).

PITTSBURGH , March 29, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced participation in two upcoming virtual conferences. Details for the presentations are as follows: Guggenheim Healthcare Talks:

-  Initial data from Cohort 1 of the PEARL-1 study shows safety and tolerability of repeat KB301 injections -  Dr. Bhushan Hardas M.D ., MBA appointed President, Jeune, Inc. PITTSBURGH , March 24, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable

- Enrollment anticipated to complete in 1Q21 and topline pivotal data from the GEM-3 study of B-VEC in DEB expected in 4Q21. - Today announced Positive Opinion from the European Medicines Agency on Orphan Drug Designation for KB407 for the treatment of cystic fibrosis.

PITTSBURGH , Feb. 23, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that Krish S. Krishnan , Chairman and Chief Executive Officer will be participating in a fireside chat at the 41 st Annual

PITTSBURGH , Feb. 02, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. (NASDAQ: KRYS) (the “Company), the leader in redosable gene therapies for rare diseases, today announced that it has priced the previously announced underwritten public offering of 1,923,077 shares of its common stock, at a public

PITTSBURGH --(BUSINESS WIRE)--Feb. 2, 2021-- Krystal Biotech Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has commenced a $100 million underwritten public offering of its common stock.

PITTSBURGH --(BUSINESS WIRE)--Jan. 4, 2021-- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases today announced the appointment of Chris Mason , MD, PhD, FRCS, FMedSci, and Jing L. Marantz , MD, PhD, MBA to its board of directors.

PITTSBURGH --(BUSINESS WIRE)--Nov. 24, 2020-- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in non-invasive, redosable gene therapies, today announced that Krish S. Krishnan , chairman and chief executive officer will be participating in a fireside chat at the Evercore ISI 3rd

- Pivotal GEM-3 study of B-VEC in DEB expected to complete enrollment in early 2021 - Initiated the Phase 1 Study of KB301 in Facial Wrinkles and Acne Scars - Today announced additional in vivo preclinical data supporting the development of KB407 in cystic fibrosis - Strong balance sheet with cash,

PITTSBURGH --(BUSINESS WIRE)--Oct. 16, 2020-- Krystal Biotech , Inc. (Nasdaq:KRYS) today announced that Chief Commercial Officer Jennifer Chien is leaving the company, effective today, to pursue another opportunity. Senior members of Krystal’s commercial team will report directly to Chief Executive

- KB301 is designed to deliver a full-length human type 3 collagen transgene via injection - The Phase 1 PEARL-1 clinical study to evaluate KB301 in acne scars and fine wrinkles is currently enrolling PITTSBURGH --(BUSINESS WIRE)--Oct. 8, 2020-- Krystal Biotech , Inc.

PITTSBURGH --(BUSINESS WIRE)--Sep. 24, 2020-- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced that Krish S.